Key facts
- Evolyra Therapeutics’s last known valuation is $48.0M (Jul 2025).
- It has raised $5.0M; the latest was Early Stage VC ($20.0M) in Apr 2026.
- Notable investors include Impact Assets.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Evolyra Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Evolyra Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Evolyra Therapeutics
Developer of small-molecule therapeutics designed to target disease-causing proteins through precision drug discovery approaches. The company's therapeutics platform develops small-molecule drug candidates designed to selectively target and modulate disease-related proteins using structure-based discovery methodologies, enabling clinical researchers and healthcare providers to advance treatment strategies in oncology and other serious diseases.
- Sector
- Healthcare
- HQ
- Richmond, VA, United States
- Website
- evolyratherapeutics.com/
- Ownership
- Privately Held (backing)
Evolyra Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Evolyra Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Evolyra Therapeutics in its N-PORT filings yet. We sweep new filings monthly.